ENANTA PHARMACEUTICALS, INC Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
ENANTA PHARMACEUTICALS, INC (ENTA) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$14.99 million for the 12-month period ending 2025-09-30, per its 10-K filed 2025-11-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2025-11-19
- ENANTA PHARMACEUTICALS, INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was -$14.99M.
- ENANTA PHARMACEUTICALS, INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was -$12.12M.
- ENANTA PHARMACEUTICALS, INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was -$47.39M.
- ENANTA PHARMACEUTICALS, INC valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was -$38.43M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 9 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|---|
| 2025-09-30 | -$14.99M 10-K · filed 2025-11-19 | |
| 2024-09-30 | -$12.12M 10-K · filed 2025-11-19 | |
| 2023-09-30 | -$47.39M 10-K · filed 2025-11-19 | |
| 2022-09-30 | -$38.43M 10-K · filed 2024-11-27 | |
| 2021-09-30 | -$11.04M 10-K · filed 2023-11-22 | |
| 2020-09-30 | $0.00 10-K · filed 2022-11-23 | |
| 2014-06-30 | $15.33M 10-K · filed 2014-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |